China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Britain Courts Anthropic Amid US Defense Department Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
MALVERN, Pa., Aug. 01, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its first quarter financial results before the market open on August 8, 2017
Management will conduct a conference call at 8:30 AM ET that day to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 54200846 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
